

Online Appendix 1

Supplementary On-Line Table 1. Baseline and 26 Week Values for Quality of Life Measures for the CGM Group Stratified by CGM Use in Month 6 of the Trial

		CGM Use \geq 6 days/week in Month 6			CGM Use $<$ 6 days/week in Month 6			
		Enrollment	26 weeks	Difference*	Enrollment	26 Weeks	Difference*	
	N†	Mean \pm SD	Mean \pm SD	Mean \pm SD	N†	Mean \pm SD	Mean \pm SD	Mean \pm SD
Participants \geq18 years								
HFS-Total score ‡	78	37.8 \pm 12.6	33.6 \pm 11.7	-4.2 \pm 8.7	42	37.1 \pm 13.3	32.9 \pm 11.3	-4.3 \pm 12.8
HFS-Worry subscale §	78	31.3 \pm 18.5	26.4 \pm 16.5	-5.0 \pm 11.3	42	28.7 \pm 17.7	23.3 \pm 14.6	-5.4 \pm 14.4
HFS-Behavior subscale	78	46.2 \pm 10.9	43.0 \pm 10.7	-3.2 \pm 9.6	42	48.1 \pm 11.3	45.3 \pm 12.3	-2.8 \pm 12.4
PAID ¶	78	22.5 \pm 13.7	17.1 \pm 12.9	-5.4 \pm 9.9	42	23.7 \pm 18.0	20.0 \pm 16.2	-3.7 \pm 13.0
SF-12-PCS #	78	53.8 \pm 5.2	55.8 \pm 4.5	+2.0 \pm 6.0	42	54.7 \pm 7.2	55.1 \pm 5.7	+0.4 \pm 5.8
SF-12-MCS **	78	49.5 \pm 7.7	48.3 \pm 10.6	-1.3 \pm 10.3	42	49.2 \pm 9.6	48.8 \pm 9.4	-0.4 \pm 8.2
Participants $<$ 18 years								
HFS-Worry Subscale §	43	24.9 \pm 15.2	18.8 \pm 11.8	-6.1 \pm 12.0	60	26.3 \pm 17.8	22.3 \pm 13.9	-4.0 \pm 12.6
PedsQL Generic††	43	80.8 \pm 11.5	83.9 \pm 11.0	+3.2 \pm 11.5	59	76.9 \pm 13.1	78.1 \pm 12.8	+0.9 \pm 9.0
PedsQL Diabetes-Specific‡‡	43	84.3 \pm 11.6	85.1 \pm 10.4	+0.9 \pm 8.3	59	80.6 \pm 12.5	79.1 \pm 14.0	-1.8 \pm 10.8
Parents§§								
HFS-Worry subscale §	45	42.1 \pm 13.9	37.0 \pm 13.9	-5.2 \pm 13.3	62	40.8 \pm 17.5	37.0 \pm 15.2	-3.5 \pm 13.2
Parent-PAID¶¶	45	48.6 \pm 12.3	47.0 \pm 13.2	-1.6 \pm 13.2	62	45.1 \pm 14.8	47.3 \pm 12.4	+2.6 \pm 13.2
PedsQL Generic††	45	74.9 \pm 11.1	77.3 \pm 13.4	+2.4 \pm 11.1	62	77.9 \pm 12.2	76.4 \pm 12.1	-1.6 \pm 10.9
PedsQL Diabetes-specific‡‡	45	75.3 \pm 11.0	77.9 \pm 11.2	+2.6 \pm 11.6	62	76.3 \pm 12.9	75.4 \pm 11.9	-1.4 \pm 12.3

† None of the p values from the ANCOVA comparing the difference after 26 weeks for the regular users (\geq 6 days/week) vs. the less frequent users ($<$ 6 days/week) were $<$ 0.05.

* These analyses were limited to subjects or parents who completed both baseline and 26-week questionnaires.

‡ Hypoglycemia Fear Survey (HFS) average score of all items giving equal weight to each item. Scale 0-100 with higher score denoting more fear or more likely to avoid low blood glucose.

§ HFS Worry subscale. Scale 0-100 with higher score denoting more fear.

|| HFS Behavior subscale. Scale 0-100 with higher score denoting more likely to avoid low blood glucose.

¶ Problem Areas in Diabetes Scale (PAID). Scale 0-100 with higher score denoting more problems.

Social Functioning SF-12 version 2 Health Survey (SF-12) - Physical Component Summary (PCS). Norm based score with higher score denoting better functioning.

** SF-12 - Mental Component Summary (MCS). Norm based score with higher score denoting better functioning.

†† Pediatric Quality of Life (PedsQL) Survey Generic Core Scales (Emotional, Social, and School functioning subscales). Scale 0-100 with higher score denoting higher quality of life.

‡‡ PedsQL Survey Type 1 Diabetes Module (Treatment Barriers, Treatment Adherence, and Worry subscales). Scale 0-100 with higher score denoting higher quality of life.

§§ Parents refer to parents of participants <18 years of age.

The JDRF Continuous Glucose Monitoring Study Group

Clinical Centers: Listed in order of number of patients enrolled with clinical center name, city, and state. Personnel are listed as (PI) for Principal Investigator, (I) for co-Investigator and (C) for Coordinators:

Diabetes Care Center, University of Washington, Seattle, WA: Irl B. Hirsch, M.D. (PI); Lisa K. Gilliam, M.D., Ph.D. (I); Kathy Fitzpatrick, R.N., M.N., C.D.E. (C); Dori Khakpour, R.D., C.D., C.D.E. (C); *Department of Pediatrics, Yale University School of Medicine, New Haven, CT:* Stuart A. Weinzimer, M.D. (PI); William V. Tamborlane, M.D. (I); Brett Ives, M.S.N., A.P.R.N. (C); Joan Bosson-Heenan (C); *Adult Section, Joslin Diabetes Center, Boston, MA:* Howard Wolpert, M.D. (PI); Greeshma Shetty, M.D. (I); Astrid Atakov-Castillo (C); Judith Giusti, M.S., R.D., L.D.N., C.D.E. (C); Stacey O'Donnell, R.N., C.D.E. (C); Suzanne Ghiloni, R.N., C.D.E. (C); *Atlanta Diabetes Associates, Atlanta, GA:* Bruce W. Bode, M.D. (PI); Kelli O'Neil, C.D.E. (C); Lisa Tolbert, R.N., M.N., C.D.E. (C); *Nemours Children's Clinic, Jacksonville, FL:* Tim Wysocki, Ph.D. (co-PI); Larry A. Fox, M.D. (co-PI); Nelly Mauras, M.D. (I); Kimberly Englert, R.N. (C); Joe Permuy, M.S.N., A.R.N.P. (C); *Division of Pediatric Endocrinology and Diabetes, Stanford University, Stanford, CA:* Bruce Buckingham, M.D. (PI); Darrell M. Wilson, M.D. (I); Jennifer Block, R.N., C.D.E. (C); Kari Benassi, R.N., N.P. (C); *Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA:* Eva Tsalikian, M.D. (PI); Michael Tansey, M.D. (I); Debra Kucera, A.R.N.P., C.P.N.P. (C); Julie Coffey, A.R.N.P., C.P.N.P. (C); Joanne Cabbage (C); *Pediatric Adolescent, and Young Adult Section, Joslin Diabetes Center, Boston, MA:* Lori Laffel, M.D., M.P.H., (PI), Kerry Milaszewski, R.N., C.D.E. (C); Katherine Pratt (C); Elise Bismuth, M.D., M.S., (C); Joyce Keady, M.S.N., C.P.N.P. (C); Margie Lawlor, M.S., C.D.E. (C); *Barbara Davis Center for Childhood Diabetes, University of*

Colorado, Denver, CO: H. Peter Chase, M.D. (PI); Rosanna Fiallo-Scharer, M.D. (I); Paul Wadwa, M.D. (I); Laurel Messer, R.N., C.D.E. (C); Victoria Gage, R.N. (C); Patricia Burdick (C); *Departments of Pediatric Endocrinology and Research and Evaluation, Kaiser Permanente, San Diego and Pasadena, CA:* Jean M. Lawrence, Sc.D., M.P.H., M.S.S.A. (co-PI); Robert Clemons, M.D. (co-PI); Michelle Maeva, R.N., C.D.E. (C); Bonnie Sattler, M.S., R.D. (C); *Coordinating Center:* Jaeb Center for Health Research, Tampa, FL: Roy W. Beck, M.D., Ph.D.; Katrina J. Ruedy, M.S.P.H.; Craig Kollman, Ph.D.; Dongyuan Xing, M.P.H.; Judy Sibayan, M.P.H.; *University of Minnesota Central Laboratory:* Michael Steffes, M.D., Ph.D., Jean M. Bucksa, C.L.S., Maren L. Nowicki, C.L.S., Carol Van Hale, C.L.S., Vicky Makky, C.L.S. *Cost-effectiveness investigators: National Opinion Research Center, University of Chicago:* Michael O'Grady, Ph.D.; Elbert Huang, M.D., M.P.H.; Anirban Basu, Ph.D.; David O. Meltzer, M.D., Ph.D.; Lan Zhao, Ph.D. *University of Michigan:* Joyce Lee, M.D., M.P.H. *Juvenile Diabetes Research Foundation, Inc.:* Aaron J. Kowalski, Ph.D. *Operations Committee:* Lori Laffel, M.D., M.P.H. (co-chair), William V. Tamborlane, M.D. (co-chair), Roy W. Beck, M.D., Ph.D., Aaron J. Kowalski, Ph.D., Katrina J. Ruedy, M.S.P.H. *Data and Safety Monitoring Board:* Ruth S. Weinstock, M.D., Ph.D. (chair), Barbara J Anderson, Ph.D.; Davida Kruger, M.S.N., A.P.R.N.; Lisa LaVange, Ph.D.; Henry Rodriguez, M.D.